Category Archives: Neurotechnology

Share this story with your network

ALLENDALE, N.J.(BUSINESS WIRE)Strykers Spine division today announced that it will demonstrate its Aero-C Cervical Stability System (Aero-C) and Xia 4.5 Cortical Trajectory implants and instruments (Xia CT) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 1518, 2017, in San Diego (booth No. 3133).

Aero-C, the only straight forward anterior cervical discectomy and fusion (ACDF) device that offers uniform compression across the interbody space, will be displayed at AAOS 2017, highlighting its full commercial launch. Using Aerofoil Compression Technology, Aero-C is designed to pull the vertebral bodies toward the implant as it is inserted, creating compressive forces at the implant-to-endplate interface.1 Aerofoil Compression Technology is also available for lateral and anterior lumbar interbody fusion procedures (LLIF and ALIF). Since the initial introduction to the market, over 600 cases have been completed.

Also to be demonstrated at AAOS is Xia CT, which includes implants and instruments used in less invasive LITe LIF posterior lumbar interbody fusion procedures for patients with degenerative disc disease, spondylolisthesis, and trauma. The cortical trajectory procedure facilitates a smaller midline incision to help achieve decompression, fixation, and fusion.2 It also is intended to be more muscle sparing than standard open procedures that require lateral dissection, and its reduced incision may allow for more efficient exposure and closure time.2 The launch of the Xia CT system occurred in 2016, with 575 cases completed to date.

Since their introduction last year, Aero-C and Xia CT have been well received by our surgeon customers and have achieved rapid adoption in the marketplace, said Bradley Paddock, President of Strykers Spine division. These unique products reflect our strong commitment to advancing spine health and helping to enhance outcomes for patients by providing physicians with innovative and differentiated technology.

Aero-C and Xia CT offer advancements that highlight the Spine divisions leadership in pioneering innovative technologies for traditional and minimally invasive surgical techniques. The company offers one of the most comprehensive and diverse product portfolios for the treatment of degenerative and complex spinal disorders. Its suite of leading-edge products includes implants, instruments, and biologics for the cervical, thoracic, and lumbar spine.

About Stryker

Stryker is one of the worlds leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

References

Indications for Use

The AERO-C Cervical Cage is indicated for use in cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from the C2-C3 disc to the C7-T1 disc. The AERO-C Cervical Cage System is to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, and is to be implanted via an open, anterior approach.

The Xia CT implants and instruments are intended for anterior/anterolateral and posterior, non-cervical pedicle and non-pedicle fixation for the following indications: Degenerative Disc Disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies); spondylolisthesis; trauma (i.e. fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudarthrosis; failed previous fusion.

Content ID: CVAER-PR-2_13458

The rest is here:

Stryker's Spine division to exhibit key technologies at AAOS 2017 - OrthoSpineNews

Photo: ReThinkX

The MedX Future of Healthcare conference will be held on 25th March at Citylabs 1.0, ran by ReThinkX, which aims to bridge the gap between the next generation and leaders of the field and to create an accessible medium to showcase the technology at the forefront of healthcare.

Tariq Ramtoola, Director of ReThinkX, says: We will have speaker panels running in the same time as workshops in order for people to feel more free to choose what mood they are in: listening to innovative speakers, be more hands on, be enthusiastic and debate, or even just relax in the chill-out area. There will be something for everybody!

We think traditional conferences are too rigid and set the agenda for attendees, says Ramtoola on the format of the conference.

Keynotes on the day include Hugo Mercier, CEO & co-founder of Rythm, a neurotechnology company that has made the first active wearable headband to help improve sleep. The Dreem headband is due to be available to consumers soon.

Also speaking is Dr Pablo Rojo, a Paediatric Infectious Diseases Specialist from Madrid. Previously Dr Rojo is part of the EPIICAL project, which aims to provide new therapeutics to early treated HIV-infected children, and has published over 80 peer-reviewed articles in his career.

Unlike other events of its kind, the MedX conference is free for students, but limited priced tickets are available for academics and professionals in the healthcare field. Explaining this decision, Ramtoola says that ReThinkX wanted to put great emphasis on accessibility.

Workshops will also be held throughout the day, including one by GMC which will challenge the ethical implications of social media and a digital world, led by Tista Chakravarty-Gannon, GMCs Principal Regional Liaison Advisor.

Bella Eacott, Research and Curriculum Manager at Clod Ensemble, and Suzy Wilson, Director of Performing Medicine, an education programme led by a theatre company will be holding a Circle of Care workshop, looking at art based methods in healthcare education.

In the future, ReThinkX hope to grow the conference so that it spans two days with 500 to 1000 delegates.

We are working with Manchester entrepreneurs, Manchester Science Partnerships and the North-West Biotech Initiative to create an entrepreneurship academy focused on small scale innovation, Ramtoola says.

Tickets are available here.

Go here to read the rest:

Preview: MedX Future of Healthcare conference - The Mancunion

Share this story with your network

Allendale, N.J.March 8, 2017Strykers Spine division will feature its 3D-printed Tritanium Posterior Lumbar (PL) Cage and introduce a variety of new cage sizes at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 15-18, 2017, in San Diego (booth No. 3133).

Strykers Tritanium PL Cage launch initially included four footprint options, eight height options, and two lordosis options. The company now offers several additional sizes based on surgeon needs and requests, including a hyper-lordotic (12) cage option, as well as two new footprints9 x 32 mm and 11 x 32 mm.

During the conference, Strykers proprietary Tritanium In-Growth Technology will be featured in a virtual reality tour, providing surgeons with a unique perspective on how 3D printing, also known as additive manufacturing, allows the company to produce highly porous implants that would be difficult or impossible to create using traditional manufacturing techniques.

Tritanium Technology allows for the creation of porous structures designed to mimic cancellous bone in pore size, level of porosity, and interconnectivity of the pores.1 This precise randomization1 of fully interconnected pores differs from other technologies featuring longitudinal channels and traverse windows that result in a uniform lattice structure, as well as cages offering porosity that is only present on the surface.

Stryker is a pioneer in 3D additive manufacturing, investing nearly 15 years in research and development, said Strykers Spine division President Bradley Paddock. Unlike traditional manufacturing techniques, the flexibility of our 3D additive manufacturing capabilities allows us to precisely engineer and produce porous Tritanium devices. We are excited to continue growing our unique suite of Tritanium spinal products.

Also at AAOS, results will be presented from a pre-clinical animal study that evaluated the biomechanical performance and bone in-growth potential of various lumbar interbody fusion implants utilizing different materials, including the Tritanium PL Cage. Preliminary results of the study were presented at the North American Spine Society conference in October 2016. (Click here to access the Tritanium pre-clinical study summary.)

The Tritanium PL Cage features fully interconnected pores that span endplate to endplate. Its large lateral windows and open architecture allow visualization of fusion on CT and X-ray,2 and its solid-tipped, precisely angled serrations are designed to allow for bidirectional fixation and to maximize surface area for endplate contact with the cage. Additional spinal implants based on Strykers Tritanium Technology are in development.

About StrykerStryker is one of the worlds leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. For more information, visitwww.stryker.com or http://www.stryker.com/builttofuse.

Media ContactBarbara Sullivan, Sullivan & Associatesbsullivan@sullivanpr.com, 714/374-6174

Editors note: For images, video footage, or animation of the Tritanium PL Cage and Strykers 3D additive manufacturing process, contact Barbara Sullivan at bsullivan@sullivanpr.com or 714/374-6174.A backgrounder is available at http://www.stryker.com/builttofuse.

References

Content ID: TRITA-PR-6_13360

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: AMagine, Stryker, Tritanium. All other trademarks are trademarks of their respective owners or holders.

Josh Sandberg has been an executive search consultant focused exclusively on orthopedic and spine start-ups since 2004. He has had a tremendous impact in helping his clients avoid costly hiring mistakes by his deep industry knowledge and network. In 2010, Josh co-founded Ortho Spine Companies, which is the parent company of Ortho Spine Distributors (OSD), Surg.io and Ortho Sales Partners (OSP). OSD a searchable database that helps ease the frustration of finding orthopedic distributors throughout the country. Surg.io is the ultimate distributor toolkit that offers distributors the tools necessary to build the foundation of a scalable and highly functioning sales organization. OSP is an end-to-end solution that helps companies approach the Global Market in a cost efficient way. Our team has hundreds of years of experience and can help you navigate the many challenges present in bringing new technologies to the market.

Read the original:

Stryker's Spine Division To Feature Novel 3D-Printed Spinal Implants at AAOS Conference - OrthoSpineNews

RBC Capital Markets Boosts Stryker Co. (SYK) Price Target to $135.00 Chaffey Breeze The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. and more »

More:

RBC Capital Markets Boosts Stryker Co. (SYK) Price Target to $135.00 - Chaffey Breeze

Even simple communication is a constant struggle for paralyzed patients, but a collaborative project from BrainGate neurotechnology researchers, which included scientists from Brown, recently found a way for these patients to type at the fastest speeds achieved yet.

Imagined actions, such as moving a cursor across an on-screen keyboard and selecting a letter, have become a reality for paralyzed patients with the help of a brain-computer interface.

Researchers implanted a tiny array of 100 electrodes in the brain so only the top of a silver plug was visible outside the patients skull. These electrodes recorded the firing of certain cells inside the brain and sent the information through a series of wires and connectors to reach a decoder a computer system that interprets the information, said Leigh Hochberg 90, professor of engineering.

The most recent data from the ongoing research shows that typing assisted by brain-computer interfaces is approaching speeds that would be useful for the public, Hochberg said. For patients who cannot move or speak, even the ability to say yes or no is meaningful communication, he added.

The three subjects were able to type at 1.4 to 4.2 times the speeds previously achieved by paralysis patients using similar systems, according to the study. With the interface, one subject reached a typing speed of nearly eight words per minute. All three typed at rates above 3.5 words per minute, which would satisfy the majority of paralysis patients, wrote Chethan Pandarinath, postdoctoral fellow at Stanford University and lead author of the study, in an email to The Herald.

Though these typing speeds are the fastest yet, they remain painfully slow, said Elizabeth Tyler-Kabara, director of the Neural Enhancement Laboratory at the University of Pittsburgh. Predictive typing systems, like those that complete your words and phrases as you text, might increase those speeds dramatically, she added.

Advances in machine learning and artificial intelligence could also enhance the interfaces, allowing for more natural control, Pandarinath wrote.

The interface is not yet a marketable device, said Paul Nuyujukian, director of the Brain Interfacing Laboratory at Stanford and co-author of the study. The interface needs to be able to work anywhere, without wires or a trained technician, he added.

Still, this increase in typing speed is a hugely significant increase, said Michael Boninger, vice chair for research at the University of Pittsburgh Medical Center. Theres no doubt that this brain-computer interface work has the ability to be transformative.

Researchers in multiple locations across the country have engaged in human research with this implanted chip since around 2004, Hochberg said. More recently, the team developed algorithms for the decoder that allowed subjects to point and click on a screen, he added.

BrainGate researchers and other experts not involved with the project noted the studys reliance on the research participants. Through their generous feedback about the device, they allow scientists to help more people with paralysis in the future, Hochberg said.

The subjects are heroic, Nuyujukian said. All of medicine owes them a huge debt of gratitude.

Continued here:

Paralysis patients achieve fastest typing yet with new brain-computer interface - The Brown Daily Herald

Share this story with your network

Kalamazoo, Michigan, USA March 7, 2017 Stryker announced today that its AVAflex Balloon System has received FDA 510(k) clearance and is, for the first time, available with Strykers market-leading bone cements and implants and the AutoPlex Mixing and Delivery System.

Doctors who perform vertebral augmentations are committed to the health and wellness of their patients, and Stryker is committed to empowering those doctors to provide the best possible care, said Chad Ludwig, marketing director at Stryker Instruments. The AVAflex Balloon System enables doctors to achieve bipedicular results with a unipedicular approach to vertebral augmentation.

The AVAflex and AutoPlex systems are used in the treatment of vertebral compression fractures (VCF), which affect an estimated 750,000 Americans each year. VCF patients can suffer from extreme pain and are at an increased risk for serious health problems. Vertebral augmentation, including the use of a balloon system, has been shown to provide patients with significant pain relief and dramatically reduce mortality rates.,

The AVAflex curved balloon systems new 11-gauge size allows surgeons to achieve with one insertion and a smaller needle what had previously required two insertions, making procedures less invasive and potentially reducing the risk of patient trauma. Using a minimally invasive technique, physicians can successfully create a midline cavity for targeted cement placement by accessing one pedicle.

AVAflex is now available with Strykers bone cements and implants and the AutoPlex Mixer and Delivery System, an easy-to-use bone cement mixing and delivery system. The AutoPlex system provides consistent and thorough blending of components, helping eliminate human error and variability.

Stryker has furthered its mission of making health care better for physicians, hospital staff and patients with the addition of the AVAflex portfolio, which it acquired from Becton Dickinson in 2016. Stryker provides the most complete and least invasive portfolio of vertebral compression fracture treatment options.

With an unrivaled collection of balloon catheters and augmentation options, cements, automated mixers and directional delivery systems, Stryker enables care providers to tailor their approach for the treatment of vertebral compression fractures. Stryker is now the exclusive provider of automatic mixing and delivery systems and 11-gauge curved balloons.

About Stryker

Stryker is one of the worlds leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

Josh Sandberg has been an executive search consultant focused exclusively on orthopedic and spine start-ups since 2004. He has had a tremendous impact in helping his clients avoid costly hiring mistakes by his deep industry knowledge and network. In 2010, Josh co-founded Ortho Spine Companies, which is the parent company of Ortho Spine Distributors (OSD), Surg.io and Ortho Sales Partners (OSP). OSD a searchable database that helps ease the frustration of finding orthopedic distributors throughout the country. Surg.io is the ultimate distributor toolkit that offers distributors the tools necessary to build the foundation of a scalable and highly functioning sales organization. OSP is an end-to-end solution that helps companies approach the Global Market in a cost efficient way. Our team has hundreds of years of experience and can help you navigate the many challenges present in bringing new technologies to the market.

Go here to see the original:

Stryker's AVAflex Vertebral Balloon System Receives FDA 510(k) Clearance - OrthoSpineNews

The human brain is the mostcomplex system in the known universe. It is imbued with enormous potential that we have yet to fully understand or to harness. But were making progress, for many good reasons.

By studying how the human brain functions and how it responds to stimuli, we can potentially train our minds for optimal performance and, perhaps, overcome physical disabilities or detect neurological abnormalities for treatment. We stand now on the cusp of what has been called The Fourth Industrial Revolution, a revolution that is growing out of the integration of the physical, digital and biological realms. The ability to directly connect electronic devices to the human organism in order to affect physical objects around us has the potential to drive change forward at an exponentially increasing pace. Our understanding of our limitations will be shattered, and new vistas will open up, as we explore the possibilities that arise when we bring minds, machines, and the material world together.

Put simply, we stand to reap enormous benefits if we can enlighten ourselves as to why and how we think and feel - to improve how we interact with and experience the world around us.

Today, innumerable such efforts proceed in specialised laboratories around the world, with a rather limited number of research subjects. But everyones brain is unique and changing in unique ways. The term neuroplasticity means that our brains change shape and function based on personal biological factors as well as our individual experiences in life. So were likely to gain commensurately greater insights from a broader participation in such studies.

And thats where brain wearables come into the picture.

A market for brain wearables has promised to put neurotechnology into the hands of ordinary people. This is important because of the uniqueness of every brain; the greater the sample, the more robust the insights it yields.

Today these devices fall into two main categories. One uses electroencephalograms (EEGs) essentially, surface brain wave activity in a non-invasive, read-only mode, which can provide data on the wearers mental and emotional state. The other basic approach relies on transcranial direct current stimulation (TDCS), which sends electrical signals to the brain for neuro-priming, which is intended to promote hyper-learning.

I work in the EEG-related field of brain wearables, which offer a means to further our understanding of the human brain in a useful form factor and at a reasonable price point.

We are using brain wearables to conduct longitudinal studies over time in more than 120 countries to discern how different stimuli and situations affect different brains, helping us understand, for instance, how different people react to handling stress or how we can assist them in achieving optimal performance.

In practical terms, understanding and encouraging high performance is one focus of our work, which would have obvious benefits for athletes, soldiers, professionals, artists nearly everyone, really. And the broadest possible application would be to gain a better understanding of how various stimuli and our own, often very individual responses affect our thoughts and feelings. The end result could be to inform an improved self-awareness and a better understanding of ourselves to mitigate irrational or unproductive behaviour.

Ultimately, those of us in the brain wearables field would like to make progress on the early detection of neurological issues and overall brain health.

One in three people, of the more than seven billion on Earth, are affected by brain-related illnesses, including depression, anxiety, dementia, autism, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), stroke or trauma. Apart from widespread human suffering, these disorders are estimated to cost the global economy some $2 trillion per year. In the U.S., specifically, an aging population has the potential for extended lives, for which quality-of-life will require healthy brains.

Brain health is also considered a key factor in many other bioinformatics advances. I think of it as a quintessential 21st century issue.

Though Im positively buoyant about the known and potential benefits of brain wearables, it is also our duty to be vigilant about the potential risks.

Data privacy and security are perennial concerns for everyone. These concerns are heightened when personal health-related matters are at stake. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides legal protections and it is up to technologists to ensure that data privacy and security protections are state of the art.

Currently we are careful to apply significant effort and care to user consent issues for participation in studies we conduct. The critical issue, in my view, is preserving individual choice and the personal integrity of every individual.

I have few real concerns at this stage, because wearables are just that; you can put them on or take them off and anonymising data in studies is standard practice. But if brain wearables or related technologies were to become embedded in the human body, theres an obvious risk of abuse. Today, arguably, our thoughts and feelings are our own, but we know that chemical reactions govern these and thus they could be manipulated, leading to a loss of individuality.

Our approach is the opposite of a dystopian use of brain monitoring technology. Our philosophy is to democratize technology and make tools such as brain wearables more affordable, easier to use. Our technology platform is based on open access software (e.g., extensible APIs), aimed at both broad uptake (if the market finds them useful), and the broadest possible base of innovation to benefit all. We want to avoid creating another aspect of a digital divide, with brain wearables available only to a few who can afford them. We believe this approach is in step with societys shared values.

We work with partners across many domains and more than 120 countries, an open acknowledgement that we dont have all the answers. The direction that brain wearables take is not up to us as pioneers in the field. Its an open conversation. We simply want to position the technology and raise awareness for the greatest breadth and depth of potential contributions to the field. The more participants in brain wearable trials the more we learn about the behavior of the human brain and ways in which its health and optimal use can be encouraged.

Widespread adoption is the crux of our success. A broad and diverse dialogue on the issues of brain health and technology will enable the enhancement of healthy brains and detect signs of cognitive decline and disorders.

Continued here:

How 'brain wearables' can address 21st century needs - IoT Tech News

In a report released on 03/03/2017 RBC Capital Markets bumped up the target of Stryker Corporation (NYSE:SYK) from $129.00 to $135.00 indicating a possible upside of 0.04%.

Previously on 1/25/2017, Canaccord reported about Stryker Corporation (NYSE:SYK) increased the target price from $127.00 to $137.00. At the time, this indicated a possible upside of 0.13%.

Yesterday Stryker Corporation (NYSE:SYK) traded -0.20% lower at $130.24. Stryker Corporations 50-day average is $124.46 and its two hundred day average is $117.54. With the last stock price up 11.27% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. Trade Volume was down over the average, with 940,446 shares of SYK changing hands under the typical 1,320,280

With a total market value of $0, Stryker Corporation has price-earnings ratio of 30.07 with a one year low of $98.00 and a one year high of $131.36 .

A total of 24 analysts have released a research note on SYK. Nine analysts rating the company a strong buy, eight analysts rating the company a buy, nine analysts rating the company a hold, two analysts rating the company a underperform, and finally 1 firm rating the stock a sell with a consensus target price of $116.50.

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Read more:

A report released today by RBC Capital Markets about Stryker Corporation (NYSE:SYK) ups the target price to $135.00 - Breaking Finance News

Yesterday Stryker (NYSE:SYK) traded -0.20% lower at $130.79. The companys 50-day moving average is $124.46 and its 200-day moving average is $117.54. The last stock close price is up 11.27% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 940,446 shares of the stock were exchanged, down from an average trading volume of 1,320,280

Stryker (NYSE:SYK) had its target price raised to $135.00 by RBC Capital in a report released 3/3/2017. The new target price indicates a possible upside of 0.03% based on the company's last stock close price.

Previously on Wednesday January 25, 2017, Canaccord reported about Stryker (NYSE:SYK) raised the target price from $127.00 to $137.00. At the time, this indicated a possible upside of 0.13%.

Stryker has a price-earnings ratio of 30.07 with a one year low of $98.00 and a one year high of $131.36 The companys market cap is currently $0.

In addition to RBC Capital reporting its stock price target, a total of 24 analysts have released a research note on SYK. The one year target is $116.50 with nine analysts rating the company a strong buy, eight equity analysts rating the company a buy, nine equity analysts rating the company a hold, 2 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Go here to see the original:

Stryker (NYSE:SYK) target price raised to $135.00, reported today ... - Breaking Finance News

Wall Street Journal (subscription) (blog)

What Health Care Can Learn from Wal-Mart Wall Street Journal (subscription) (blog) Consumer companies avail themselves of psychology, anthropology and even neurotechnology, ironically using medical principles and equipment to influence our behaviors in a way the medical world is not. I'm not one to systematically dismiss surveys, ...

Read more:

What Health Care Can Learn from Wal-Mart - Wall Street Journal (subscription) (blog)